Rev Proteins of Human and Simian Immunodeficiency Virus Enhance RNA Encapsulation

Sabine Brandt*, Maik Blißenbach*, Bastian Grewe, Rebecca Konietzny, Thomas Grunwald, Klaus Überla*

Department of Molecular and Medical Virology, Ruhr-University Bochum, Germany

The main function attributed to the Rev proteins of immunodeficiency viruses is the shuttling of viral RNAs containing the Rev responsive element (RRE) via the CRM-1 export pathway from the nucleus to the cytoplasm. This restricts expression of structural proteins to the late phase of the lentiviral replication cycle. Using Rev-independent gag-pol expression plasmids of HIV-1 and simian immunodeficiency virus and lentiviral vector constructs, we have observed that HIV-1 and simian immunodeficiency virus Rev enhanced RNA encapsidation 20- to 70-fold, correlating well with the effect of Rev on vector titers. In contrast, cytoplasmic vector RNA levels were only marginally affected by Rev. Binding of Rev to the RRE or to a heterologous RNA element was required for Rev-mediated enhancement of RNA encapsidation. In addition to specific interactions of nucleocapsid with the packaging signal at the 5' end of the genome, the Rev/RRE system provides a second mechanism contributing to preferential encapsidation of genomic lentiviral RNA.

Introduction

Virus particles of HIV-1, the major cause of the AIDS epidemic, and other members of the lentivirus family of retroviruses contain an RNA genome. After viral entry, the genomic RNA is reverse transcribed into DNA and integrates into the genome of the host cell. The integrated proviral DNA is transcribed by RNA polymerase II. Complex alternative splicing events with a major splice donor in the 5' untranslated region (UTR) generate viral mRNAs encoding Env and a number of small regulatory proteins. The unsplitted transcript serves as a template for translation of Gag and Pol proteins. During particle formation, the unsplitted genomic RNA is also packaged in preference to spliced viral mRNAs and a more than 1,000-fold excess of cytoplasmic cellular RNAs. Packaging signals have been identified in the 5'UTR of lentiviruses (reviewed in [1]). To exclude encapsidation of spliced viral transcripts, packaging signals of retroviruses are generally located or extent 3' to the major splice donor. For members of the γ-retrovirus family, a single discrete packaging motif could be identified that was necessary and sufficient for RNA encapsidation [2]. For lentiviruses, however, the situation seems to be more complex, with several RNA motifs in the 5'UTR contributing to packaging efficiency. The major packaging signal of HIV-1 seems to be a stem loop region designated SL3, the deletion of which reduces packaging efficiency approximately 20-fold [3,4]. However, transfer of the core packaging sequences from the 5'UTR to heterologous RNAs did not allow efficient packaging of the heterologous RNA [5], suggesting that additional factors are important. In HIV-2 and simian immunodeficiency virus (SIV), the major packaging signals are located upstream of the major splice donor [6–8]. It is unclear how selective encapsidation of the genomic RNA of HIV-2 and SIV over spliced viral transcripts is accomplished. As a potential mechanism, a direct interaction between nascent Gag and its RNA template has been proposed [6]. Efficient packaging and transfer of HIV-2- and SIV-based vectors by HIV-2 particles expressed in trans demonstrates that cotranslational packaging is not an absolute requirement. Alternatively, long-distance interactions as observed for the HIV-1 5'UTR [9] might lead to different conformations of unspliced and spliced HIV-2 and SIV transcripts favouring preferential encapsidation of the unspliced transcript.

One of the small regulatory proteins expressed from a multiply spliced transcript is the lentiviral Rev protein. Rev binds to the Rev responsive element (RRE), an RNA motif present on the unsplitted transcript and the env mRNA (reviewed in [10]). By binding to the RRE, Rev shuttles the unsplitted genomic RNA and the singly spliced env-mRNA via the CRM-1 export pathway from the nucleus to the cytoplasm. The unsplitted genomic RNA then either serves as a template for translation of the gag-pol open reading frames or is packaged into the viral particle. We recently observed that omitting Rev or deleting the RRE during production of an HIV-1 vector had only a minor effect on cytoplasmic vector RNA levels, but reduced vector titers...
**Author Summary**

The AIDS pandemic is still an important public health problem, particularly in developing countries. A comprehensive understanding of the HIV replication cycle might allow development of new therapeutics. Despite 20 years of extensive research, the intracellular fate of the different RNAs produced during virus replication is not fully understood. It is known that the viral regulatory protein Rev binds to large viral RNAs and shuttles them from the nucleus to the cytoplasm by a cellular export pathway. We now provide evidence for a more far-reaching role of Rev. We observed that Rev enhances packaging of viral RNA into viral particles to a much larger extent than its effect on viral RNA levels in the cytoplasm. Thus, an early nuclear event (binding of Rev to the viral RNA) seems to be intimately linked to RNA encapsidation occurring at a late step of the viral replication cycle. Since Rev is not part of the viral particles, Rev seems to act indirectly, possibly by targeting the viral RNA to a cytoplasmic compartment favourable for RNA encapsidation. Thus, further studies on the function of Rev might also advance our understanding of cytoplasmic RNA trafficking and subcytoplasmic compartmentalization.

**Results**

**HIV-1 Rev Enhances RNA Encapsidation**

Infectious HIV-1-based vector particles were produced by cotransfection of a codon-optimized HIV-1 gag-pol expression plasmid, a VSV-G expression plasmid, a tat expression plasmid, and the prototypic HIV-1 vector construct V\textsuperscript{H} (Figure 1A) into 293T cells in the presence or absence of a rev expression plasmid [11]. Vector titers in the absence of Rev were only 3% of those obtained with Rev (Figure 2A).

To study the role of Rev on packaging efficiency, we determined genomic vector RNA levels in the cytoplasm of transfected cells and in viral particles pelleted from the supernatant of transfected cells through a 30% sucrose cushion. Mean VH vector RNA copy numbers in particles were 5.4 \times 10^8 \pm 2.0 \times 10^8 per milliliter supernatant of transfected cells with Rev, and 6.1 \times 10^6 \pm 4.6 \times 10^6 per milliliter without Rev. To normalize encapsidation for cytoplasmic RNA levels, the ratio of particle-associated RNA copies per milliliter supernatant and cytoplasmic RNA copies per microgram extracted RNA was taken as packaging efficiency. The ratio obtained for V\textsuperscript{H} in the presence of Rev was set as 100%, and the values of all other samples are given relative to this (Figure 2A). Omitting Rev reduced the packaging efficiency to 3%, while cytoplasmic RNA levels were only reduced to 44% of those

---

![Figure 1. Map of HIV-1 and SIV Vector Constructs](image_url)

**A) HIV-1**

**B) SIV**

---

**Authors:** [List of authors]

**Date:** April 2007

**Volume:** 3 | **Issue:** 4 | **E54**

---

**DOI:** 10.1371/journal.ppat.0030054.g001
obtained in the presence of Rev. Thus, Rev enhances packaging efficiency and titer of the HIV-1 vector to a similar degree.

**Rev Enhances RNA Encapsulation into SIV Particles**

Analogous experiments were also performed with an SIV vector packaging system [13] to determine whether the enhancing effect of Rev on vector RNA packaging is conserved among primate lentiviruses. Since HIV-1 Rev and Tat can functionally replace the SIV homologues, SIV vector particles were prepared by cotransfection of expression plasmids for codon-optimized *gag-pol* of SIVmac239, VSV-G, and HIV-1 *tat* with a prototypic SIV vector construct (VS in Figure 1B) in the presence and absence of the HIV-1 *rev* expression plasmid. The same enhancing effect of HIV-1 Rev on SIV vector titer and vector RNA packaging efficiency (Figure 2B) was observed, while cytoplasmic RNA levels of the SIV vector were only reduced 2-fold in the absence of Rev. To analyse whether SIV Rev also enhances RNA encapsidation, an SIV *rev* expression plasmid was cotransfected with expression plasmids for SIV *gag-pol*, VSV-G, and HIV-1 *tat*. Similar to Rev of HIV-1, SIV Rev also enhanced SIV vector RNA packaging efficiency and titer of the SIV vector (Figure 2B).

**Rev-Independent Formation of Viral Particles**

The enhanced packaging efficiency we observed in the presence of Rev could be due to stimulation of particle production and release. It has been previously observed that Rev enhances Gag protein levels in a RRE-dependent manner to a larger extent than its cytoplasmic mRNA levels [14]. Although this seemed unlikely under our experimental conditions, since codon-optimized *gag-pol* expression plasmids lacking RRE and 5'UTRs were used, we cotransfected the *gag-pol* expression plasmids of HIV-1 and SIV in three independent experiments. Relative amounts of preGAPDH RNA levels were calculated as arbitrary units (AU) per microgram extracted RNA by including 10-fold serial dilutions of standard nuclear RNA preparations. Ct values of a typical experiment are shown in the left panel, and the table summarizes the results.

**Relationship of Cytoplasmic RNA Levels and Packaging Efficiency**

The slightly reduced cytoplasmic RNA levels observed in the absence of Rev could lead to large differences in RNA packaging due to a non-linear relationship. Therefore, increasing amounts of the V\(^{\text{H}}\) vector plasmid were cotransfected with expression plasmids for HIV-1 *gag-pol*, VSV-G, and HIV-1 *tat* in the presence (±Rev) or absence (−Rev) of an HIV-1 *rev* expression plasmid. Cytoplasmic RNA levels, packaging efficiency, and vector titers are presented relative to the values obtained in the same transfection experiment with V\(^{\text{H}}\) in the presence of Rev. The mean value and standard deviation of three to eight independent transfection experiments are shown.

---

**Figure 2.** Effect of Rev on Encapsulation of HIV-1 and SIV Vector RNA

(A) The HIV-1 vector plasmid V\(^{\text{H}}\) was cotransfected with expression plasmids for HIV-1 *gag-pol*, VSV-G, and HIV-1 *tat* in the presence (±Rev) or absence (−Rev) of an HIV-1 *rev* expression plasmid. Cytoplasmic RNA levels, packaging efficiency, and vector titers are presented relative to the values obtained in the same transfection experiment with V\(^{\text{H}}\) in the presence of Rev. The mean value and standard deviation of three to eight independent transfection experiments are shown.

(B) The SIV vector plasmid V\(^{\text{S}}\) was cotransfected with expression plasmids for SIV *gag-pol*, VSV-G, and HIV-1 *tat* in the absence (−Rev) or presence of an SIV (+SIV-Rev) or HIV-1 rev (+Rev) expression plasmid. The mean value and standard deviation of four independent transfection experiments are shown. Numbers above the bars indicate fold induction by Rev.

(C) Using a real-time PCR for preGAPDH RNA, threshold cycle numbers (Ct) were determined for four nuclear (N) and cytoplasmic (C) RNA preparations in three independent experiments. Relative amounts of preGAPDH RNA levels were calculated as arbitrary units (AU) per microgram extracted RNA by including 10-fold serial dilutions of standard nuclear RNA preparations. Ct values of a typical experiment are shown in the left panel, and the table summarizes the results.

(D) Western blot analysis of total cell lysate (T), and cytoplasmic (C) and nuclear (N) fractions for Lamin B. doi:10.1371/journal.ppat.0030054.g002

---

**Table 1.** Comparison of CytoplasmicRNA Levels and Packaging Efficiency

| Exp. | AU/μg RNA | Ratio | C/N |
|------|------------|------|-----|
| 1    | 440        | 5.7  | 0.013|
| 2    | 54         | 1.2  | 0.023|
| 3a   | 25         | 3.2  | 0.127|
| 3b   | 38         | 3.1  | 0.098|
| Mean C/N ± SD | 0.092 ± 0.054 |  |  |
Effect of Rev on RNA Encapsidation in Infected Cells

The minor effect of Rev on cytoplasmic vector RNA levels could be due to overexpression of the vector RNA by transient transfection. To study the role of Rev on RNA encapsidation under more natural expression levels, 293T cells were infected with HIV-1 vector particles transferring the V\textsuperscript{H} vector, and a stable cell line, designated 293-V\textsuperscript{H}, was established. The V\textsuperscript{H} vector could be rescued from these cells at a titer of \(5.8 \times 10^4\) GFU/ml by transient cotransfection of expression plasmids for HIV-1 gag-pol, VSV-G, tat, and rev. Mean cytoplasmic vector RNA copy numbers per microgram extracted RNA were \(1 \times 10^7 \pm 4.3 \times 10^6\), and thus approximately 100-fold lower than after transient transfection of the vector construct. Even at these reduced expression levels, transfection of the rev expression plasmid only led to a 2-fold increase in cytoplasmic RNA levels (Figure 4A). In contrast, Rev enhanced packaging efficiency and the vector titer 69- and 21-fold, respectively. Similar results were obtained in cells stably infected with an SIV vector (Figure 4B).

Analysis of RRE Deletion Mutants

To determine whether the newly discovered function of Rev was dependent on interaction with the RRE, stem loop II of the RRE, which is essential for Rev binding, was replaced by a heterologous stem loop from the bacteriophage MS2 in the context of the V\textsuperscript{H} vector, resulting in V\textsuperscript{H}-MS2 (Fig 1A). Packaging efficiency and vector titers of V\textsuperscript{H}-MS2 in the presence of Rev were reduced to 9% and 18% of the values obtained with V\textsuperscript{H}, respectively (Figure 5A). Despite deletion of stem loop II of the RRE, Rev enhanced the packaging efficiency and titer of the HIV-1 V\textsuperscript{H},MS2 vector by 2.5- and 3.2-fold, respectively (Figure 5A). This minor effect of Rev could either be due to residual binding of Rev to the remaining RRE, or to a second Rev-binding site recently identified in the 5'UTR of HIV-1 [15,16]. Using an SIV vector containing a deletion of stem loop II of the SIV RRE (V\textsuperscript{H}ASL in Figure 1B), HIV-1 and SIV Rev did not enhance packaging efficiency and vector titer either (Figure 5B).

Tethering of Rev to the Vector RNA via a Heterologous RNA Element

Stem loop II of the RRE of the V\textsuperscript{H},MS2 vector had been replaced by an MS2 stem loop, which is the binding site for the coat protein of the MS2 bacteriophage. Fusion of the Rev protein to the MS2 coat protein allowed tethering of Rev to the MS2 stem loop–containing RNAs independent of the RRE [17,18]. Cotransfection of an expression plasmid for a fusion protein of Rev and the MS2 coat protein (Rev-MS2) with V\textsuperscript{H},MS2 enhanced packaging efficiency and titer of the V\textsuperscript{H},MS2 vector 11-fold (Figure 5A). Thus, Rev-mediated enhancement of encapsidation efficiency largely depends on binding of Rev to the RRE.

Discussion

The main function attributed to the Rev proteins of immunodeficiency viruses is the shuttling of viral RNAs containing the RRE from the nucleus to the cytoplasm,
allowing expression of viral structural genes [10]. The magnitude with which Rev enhanced export of RRE-containing RNAs varied greatly with experimental conditions reaching from virtually no effect of Rev on cytoplasmic RNA levels [19] over approximately 10-fold effects [14,20,21], to an absolute requirement for Rev [22]. A suboptimal level of splicing is considered to be crucial to reveal the full nuclear export function of Rev [10]. If splicing is too efficient, the RRE-containing intron is removed, and potential target mRNAs of Rev can not accumulate in the nucleus. Insufficient splicing due to a lack of recognition by splicing factors and insufficient retention in the nucleus might lead to constitutive export independent of Rev. In addition, the presence of cis-acting repressive sequences and/or instability sequences in the viral genome [23–26] most likely also influences nuclear retention and thus the degree of Rev responsiveness. However, even if comparable proviral constructs with mutations in Rev or RRE were used, the Rev effect on cytoplasmic RNA levels varied. Transient transfection experiments mostly revealed an approximately 5- to 10-fold enhancement of cytoplasmic expression levels of Rev-dependent viral RNAs [14,20,21]. In contrast, in a lymphoid cell line stably infected with a Rev-negative HIV-1, Rev-dependent RNAs could not be detected in the cytoplasm, demonstrating an absolute requirement for Rev under these experimental conditions [22]. While the transient transfection experiments could be questioned due to overexpression, a selection bias can not be formally excluded in the stably infected lymphoid cell lines. Consistent with an enhanced polysomal association of RRE-containing RNAs [20], Rev was also found to stimulate protein expression levels to a greater extent than the cytoplasmic mRNA levels encoding this protein [14].

We then observed another function of Rev, the enhancement of RNA encapsidation. Since Rev enhances cytoplasmic levels of viral genomic RNA and gag-pol expression, it is difficult to analyse the effect of Rev on steps of the viral replication cycle that depend on cytoplasmic RNA and Gag-Pol protein levels, particularly in virus-infected cells or in cells transfected with proviral expression plasmids. The use of lentiviral vector systems with codon-optimized gag-pol expression plasmids allowed us to establish experimental conditions in which gag-pol expression is completely independent of the Rev/RRE system [13]. In addition, removal of large parts of the viral genome, including cis-acting repressive sequences and/or instability sequences [23–26] from the vector construct, led to a vector RNA, the cytoplasmic expression of which was largely independent of the Rev/RRE system. Under these conditions, the influence of Rev on RNA export and expression could be avoided, and the enhancing effect of Rev on RNA encapsidation became clearly evident.

Mechanistically, enhancement of RNA encapsidation by Rev was dependent on Rev binding the vector RNA to be packaged. A functional RRE was not required, as tethering of Rev to the vector RNA via a heterologous stem loop also enhanced packaging. Since Rev is not part of the viral particle, the question of how Rev enhances RNA encapsidation arises. One attractive hypothesis is that binding of Rev to the RRE in the nucleus shuttles the viral genomic RNA via the CRM-1 export pathway to a subcytoplasmic compartment, facilitating subsequent sequence-specific interactions of the nucleocapsid of Gag with the packaging signals in the 5’UTR of the genomic RNA. Co-localization and fluorescence resonance energy transfer studies suggest a perinuclear localization for this meeting point [27]. A coupling of nuclear export and RNA encapsidation would also explain why the major packaging signals of HIV-1 are not sufficient for efficient packaging [5,28]. Although a 1.1-kb env gene fragment containing the RRE enhanced packaging in initial experiments with a vector containing an extended gag sequence [28], deletion of the RRE from the env fragment in a subsequent study with vectors containing only the first 43 nucleotides of gag reduced encapsidation levels just 2-fold [29]. Insertion of a similar env fragment into a heterologous RNA containing a fragment spanning most of HIV-1 5’UTR and a CTE from Mason-Pfizer monkey virus at the 3’ end did not lead to detectable packaging of the transcript [5]. In both of the latter publications, the RNA to be packaged might have been efficiently transported into the cytoplasm via the TAP-
Figure 5. Relevance of the Rev–RRE Interaction

(A) An HIV-1 vector plasmid in which stem loop II of the RRE was replaced by the M52 stem loop was cotransfected with expression plasmids for HIV-1 gag-pol, VSV-G, and tat in the absence (−Rev) or presence of a rev (+Rev) expression plasmid, or in the presence of an expression plasmid encoding a fusion protein of Rev and the M52 coat protein (+Rev-MSC). (B) An SIV vector with a deletion (V2’ASL in Figure 1B) of stem loop II of the RRE was cotransfected with expression plasmids for SIV gag-pol, VSV-G, and tat in the absence (−Rev) or presence of an HIV-1 (+Rev) or SIV rev expression plasmid. Cytoplasmic RNA levels, packaging efficiency, and vector titers were determined as described, and all values are expressed relative to the values obtained in the same transfection experiment for the parental V0 (A) and V2 (B) vectors in the presence of Rev, which were set as 100%. Mean value and standard deviation of at least three independent transfection experiments are shown. Numbers above the short vertical lines indicate fold induction by Rev.

doi:10.1371/journal.ppat.0030054.g005

dependent mRNA export pathway [30], preventing Rev-induced export via the CRM-1 pathway even in the presence of Rev. Despite wild-type levels of cytoplasmic RNA of RRE-deficient, CTE-containing vectors, titers were severely impaired [12]. This would suggest that export via the CRM-1 pathway is necessary for efficient packaging of the genomic RNA of lentiviruses. However, substitution of the RRE of HIV-1 by the CTE in the context of proviral expression plasmids led to efficient packaging [31]. Under these experimental conditions, nuclear export of both the gag-pol encoding RNA and the genomic RNA to be packaged are dependent on the CTE. Therefore, it seems that the packaging efficiency can also be influenced by the export pathway of the gag-pol encoding RNA. This is further supported by the observation that subcellular localization of Gag and HIV-1 virion assembly in murine cells greatly depends on the export pathway of the encoding mRNA [32]. Export of the gag-pol encoding RNA and the genomic RNA to be packaged by the same specialized export pathway might lead to enrichment of nascent Gag protein and packageable RNA in a subcytoplasmic compartment facilitating encapsidation. Although an influence of the nuclear export pathway of the gag encoding RNA on packaging efficiency and/or vector titers would reconcile results from the literature, this hypothesis needs to be addressed directly. At present, alternative hypotheses, in which Rev tethers the viral genomic RNA to Gag via bridging cellular proteins prior to dissociation of Rev from the RRE independent of the nuclear export function, can not be excluded either.

Whatever the precise mode of action, the magnitude of the effect of Rev on packaging is comparable to or exceeds the effect of deletions of parts of the multipartite HIV-1 packaging signal. Deletion of SL3, the dominant packaging domain in the 5’UTR of HIV-1, reduces RNA encapsidation approximately 20-fold [3,4], while Rev enhanced RNA packaging 23- to 69-fold. Thus, in addition to interaction of the nucleocapsid of Gag with the packaging signal at the 5’ end of the genome, the Rev/RRE system provides lentiviruses with a second mechanism contributing to preferential encapsidation of genomic RNA.

Materials and Methods

Plasmids. The HIV-1 vector constructs HIV-CLCG [33] and HIV-CLCG-MS [11] were modified by insertion of nucleotide sequences 1115 to 1329 of SIVmac239 (numbering according to GenBank entry M32902) in antisense orientation into the blunt-ended EcoNI site of the vectors generating V1’ and V3’MS2, respectively. V2’ (VCGASB in reference [34]) contains nucleotide sequences 1–2030, 8015–9499, 9689–9731, and 10057–10535 of the proviral SIVmac239 clone. Stem loop II (nucleotides 8482–8548) of the SIV-RRE was deleted by overlap extension PCR, resulting in V2’ASL. The green fluorescent protein (GFP) Blasticidin fusion gene expressing vector V2’Blas was constructed by deleting nucleotides 8899–9375 and all remaining nucleotides between 2031 and 8014 from VGBlasΔBH [35].

The expression plasmids encoding VSV-G (pHIT-G), HIV-1 tat (pcTat), HIV-1 rev (pcRev), a fusion protein of HIV-1 Rev and capsid of bacteriophage MS2 (Rev-MS2), and codon-optimized gag-pol of HIV-1 and SIV, have been described previously [13,17,36,37]. An 840-bp fragment encompassing the RRE of HIV-1 was inserted into the Xho-I site of pcUTRgp [13] to generate UT3gp-RRE.

Production and characterization of vector particles. Vector-containing particles were produced by transfection of 293T cells using the calcium phosphate coprecipitation method as described [38]. Two days after transfection, the supernatant of the transfected cells was passed through a 0.45-μm filter and stored at −80°C or used directly for titration on 293 cells [39]. Viral particles were also pelleted through a 30% sucrose cushion by ultracentrifugation and analyzed by Western blot with the HIV-1 p24-specific antibody 183-H12-5C (US National Institutes of Health [NIH] AIDS Research and Reference Reagent Program, http://www.aidsreagent.org) directed against HIV-1 and SIV capsid. The amount of pelleted p24CA was determined using the INNOTEST HIV Antigen mAb Kit (Immugenetics, http://www.immugenetics.com). To control for transfection efficiency, GFP expression was determined in lysates of transfected cells using an anti-GFP antibody (Santa Cruz Biotechnology, http://www.scbt.com). For establishment of stable cell lines 293-V1’, 293-V3’, and 293-V2’Blas, vector-containing particles were produced as described above. 293T cells were transfected with V2’ vector particles on three consecutive days. Cells were then sorted for GFP expression by flow cytometry, resulting in a population of 78% GFP-positive cells. For 293-V3’Blas cells, 293T cells were transduced once and selected for Blasticidin resistance essentially as described [35].

Packaging assay. To prepare cytoplasmic RNA, trypsinized cells were washed with PBS, and the plasma membrane was permeabilized in buffer RLN (50 mM Tris-Cl, 140 mM NaCl, 1.5 mM MgCl2, 0.5% Nonidet P-40, 1,000 U/ml RNase inhibitor, 1 mM DTT) for 5 min on
The cytoplasm was packaged approximately 500-fold less efficiently than the nuclear fraction were analyzed by Western blot using the anti-Lamin B antibodies. The cytoplasmic fraction was determined using the Bio-Rad protein assay buffer (50 mM Tris-HCl, pH 7.4; 150 mM NaCl; 40 mM NaF; 5 mM EDTA; 5 mM EGTA; 1% (v/v) Nonidet P-40; 0.1% (w/v) Natriumdesoxycholat; 0.1% (w/v) SDS)) and the cytoplasmic fraction was determined using the Bio-Rad protein assay (Bio-Rad, http://www.bio-rad.com). Next, 40 μg protein of each fraction were analyzed by Western blot using the anti-Lamin B antibody (C-20 (Santa Cruz Biotechnology). A total cell lysate was also included.

A heterologous RNA transiently expressed at comparable levels in the cytoplasm was packaged approximately 500-fold less efficiently as the vector RNAs, confirming the specificity of the packaging assay [39]. Cytoplasmic RNA levels of UTRgp-RRE were determined by an HIV-1 gag-specific RT-PCR using primers SK145 and SKCC1B from the Amplicon HIV-1 Monitor test [40].

Supporting Information

Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accession numbers for the genes and gene products discussed in this paper are HIV-1 vector pNL4-3 (AF324493), human GPDH (J04058), and simian (macaque) immunodeficiency virus, isolate 239 (M33262).

Acknowledgments
We would like to thank Ralf Wagner and Geneart (Regensburg) for providing HPP', Spp', and p51pg. Joachim Haueter for pc5at and pcRev; Sundararajan Venkatesan for the Rev-MSCl plasmid; Ulrike Blömer for HIV-CL-CG; and Michael Malim for pHIT-G. The experimental help of Marion Kauth, Bettina Tippler, and Klaus Sure is gratefully acknowledged. The following reagent was obtained through the NIH AIDS Research and Reference Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, HIV-1 p24 Hybridoma (183-H12-5C), catalog number 1513 from Bruce Chesaro and Hardy Chen.

Author contributions.
SB, MB, BG, TG, and KU conceived and designed the experiments and wrote the paper. SB, MB, BG, and RR performed the experiments. All authors analyzed the data. TG contributed reagents/materials/analysis tools. TG and KU share senior authorship.

Funding.
The authors received no specific funding for this study.

Competing interests.
The authors have declared that no competing interests exist.

References
1. Russell RS, Liang C, Wainberg MA (2004) Is HIV-1 RNA dimerization a prerequisite for packaging? Yes, no, probably? Retrovirology 1: 23.
2. Adam MA, Miller AD (1988) Identification of a signal in a murine retrovirus that is sufficient for packaging of nonretroviral RNA into virions. J Virol 62: 3892–3896.
3. Harrison GP, Miele G, Hunter E, Lever AM (1998) Functional analysis of the core human immunodeficiency virus type 1 packaging signal in a permissive cell line. J Virol 72: 5866–5873.
4. Clever JL, Parslow TG (1997) Mutant human immunodeficiency virus type 1 genomes with defects in RNA dimerization or encapsidation. J Virol 71: 3407–3414.
5. Berkowitz RD, Hammerskjold ML, Helga-Maria C, Rekosh D, Golb SP (1995) 5′ regions of HIV-1 RNA are not sufficient for encapsidation: Implications for the HIV-1 packaging signal. Virology 212: 718–723.
6. Griffin SD, Allen JF, Lever AM (1997) The major human immunodeficiency virus type 2 (HIV-2) packaging signal is present on all HIV-2 RNA species: Cotranslational RNA encapsidation and limitation of Gag protein cofactor specificity. J Virol 75: 12058–12069.
7. Strappe PM, Greatorex J, Thomas J, Biswas P, McCann E, et al. (2003) The packaging signal of simian immunodeficiency virus is upstream of the major splice donor at a distance from the RNA cap site similar to that of human immunodeficiency virus type 1 and 2. J Virol 84: 2425–2430.
8. Patel J, Wang SW, Izmailova E, Aldovini A (2003) The simian immunodeficiency virus 5′ untranslated leader sequence plays a role in intracellular viral protein accumulation and in RNA packaging. J Virol 77: 6284–6292.
9. Ooms M, Huthoff H, Russell R, Liang C, Berkhoujt B (2004) A riboswitch regulates RNA dimerization and packaging in human immunodeficiency virus type 1 virions. J Virol 78: 10814–10819.
10. Pollard VW, Malim MH (1998) The HIV-1 Rev protein. Annu Rev Microbiol 52: 491–532.
11. Lucke S, Grunwald T, Uberla K (2005) Reduced mobilization of Rev-responsive element-deficient lentiviral vectors. J Virol 79: 9359–9362.
12. Antonelli JS, Fuller MJ (2005) Rational development of a HIV-1 gene therapy vector. J Med Genet 42: 829–858.
13. Wagner R, Graf M, Bieler K, Wolf H, Grunwald T, et al. (2000) Independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: Implications for the safety of lentiviral vectors. Hum Gene Ther 11: 2405–2413.
14. Arrijo SJ, Chen IS (1991) Rev is necessary for translation but not cytoplasmic accumulation of HIV-1 vif, vpr, and env/p6RNA 2 RNAs. Genes Dev 5: 808–819.
15. Gallego J, Greatorex J, Zhang H, Yang B, Arunachalam S, et al. (2003) Rev binds specifically to a purine SLI in the 5′ leader of the HIV-1 leader RNA. J Biol Chem 278: 40385–40391.
16. Greatorex JS, Palmer EA, Pomerantz RJ, Dangerfield JA, Lever AM (2006) Mutation of the Rev-binding loop in the human immunodeficiency virus 1 leader causes a replication defect characterized by altered RNA trafficking and attenuated Gag protein expression. J Gen Virol 87: 2071–2079.
17. Venkatesan S, Gerberger SM, Park H, Holland SM, Nam Y (1992) Human immunodeficiency virus type 1 Rev activation can be achieved without Rev-responsive element RNA if Rev is directed to the target as a Rev/Ms2 fusion protein which tethers the Ms2 operator RNA. J Virol 66: 7409–7480.
18. McDonald D, Hope TJ, Parslow TG (1992) Posttranscriptional regulation by the human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type 1 Rev proteins through a heterologous RNA binding site. J Virol 66: 7232–7238.
19. Perales C, Carasco L, Gonzalez ME (2005) Regulation of HIV-1 env mRNA translation by Rev protein. Biochim Biophys Acta 1745: 169–175.
20. D'Agostino DM, Felber BK, Harrison JE, Pavlakis GN (1992) The Rev protein of human immunodeficiency virus type 1 promotes polysomal association and translation of gag/pol and vpu/env mRNAs. Mol Cell Biol 12: 1375–1386.
21. Kimura T, Hashimoto I, Nishikawa M, Fujisawa JI (1996) A role for Rev in the association of HIV-1 gag mRNA with cytoskeletal beta-actin and viral protein expression. Biochimie 78: 1075–1080.
22. Malim MH, Cullen BR (1995) Rev and the fate of pre-mRNA in the nucleus: Implications for the regulation of RNA processing in eukaryotes. Mol Cell Biol 15: 6180–6189.
23. Rosen CA, Terwilliger E, Dayton A, Sodroski JG, Haselmann WA (1988) Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus. Proc Natl Acad Sci U S A 85: 2071–2075.
24. Cochrane D, Jenkins JS, Keidis S, Dillon PJ, Skalka AM, et al. (1991) Identification and characterization of intragenic sequences which repress human immunodeficiency virus structural gene expression. J Virol 65: 3509–3513.
25. Maldarelli F, Martin MA, Strebel K (1991) Identification of posttranscriptionally active inhibitory sequences in human immunodeficiency virus type 1 RNA: Novel level of gene regulation. J Virol 65: 5752–5753.
26. Schwartz S, Felber BK, Pavlakis GN (1992) Distinct RNA sequences in the gag region of simian immunodeficiency virus: Rex-dependent inhibition of HIV-1 replication. Virology 187: 309–3041.
27. Poole E, Strappe P, Mok HP, Hicks R, Lever AM (2005) HIV-1 Gag-RNA interaction occurs at a perinuclear/centrosomal site; analysis by confocal microscopy and FRET. Traffic 6: 741–755.
28. Richardson JH, Child LA, Lever AM (1995) Packaging of human immunodeficiency virus type 1 RNA requires cis-acting sequences outside the 5′ leader region. J Virol 69: 4097–4095.
29. Kaye JF, Richardson JH, Lever AM (1995) cis-acting sequences involved in the safety of lentiviral vectors. Hum Gene Ther 11: 2403–2413.
30. D'Agostino DM, Felber BK, Harrison JE, Pavlakis GN (1992) The Rev protein of human immunodeficiency virus type 1 promotes polysomal association and translation of gag/pol and vpu/env mRNAs. Mol Cell Biol 12: 1375–1386.
31. Kimura T, Hashimoto I, Nishikawa M, Fujisawa JI (1996) A role for Rev in the association of HIV-1 gag mRNA with cytoskeletal beta-actin and viral protein expression. Biochimie 78: 1075–1080.
human immunodeficiency virus type 1 RNA packaging. J Virol 69: 6588–6592.

30. Cullen BR (2003) Nuclear RNA export. J Cell Sci 116: 587–597.

31. Helga-Maria C, Hammarskjold ML, Rekosh D (1999) An intact TAR element and cytoplasmic localization are necessary for efficient packaging of human immunodeficiency virus type 1 genomic RNA. J Virol 73: 4127–4135.

32. Swanson CM, Puffer BA, Ahmad KM, Doms RW, Malim MH (2004) Retroviral mRNA nuclear export elements regulate protein function and virion assembly. EMBO J 23: 2632–2640.

33. Miyoshi H, Blömer U, Takahashi M, Gage FH, Verma IM (1998) Development of a self-inactivating lentivirus vector. J Virol 72: 8150–8157.

34. Monse H, Laufs S, Kuate S, Zeller WJ, Fruehauf S, et al. (2006) Viral determinants of integration site preferences of simian immunodeficiency virus based vectors. J Virol 80: 8145–8150.

35. Grunwald T, Pedersen FS, Wagner R, Überla K (2004) Reducing mobilization of simian immunodeficiency virus based vectors by primer complementation. J Gene Med 6: 147–154.

36. Fouchier RAM, Meyer BE, Simon JHM, Fischer U, Malim MH (1997) HIV-1 infection of non-dividing cells: Evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO J 16: 4531–4539.

37. Malim MH, Hauber J, Fenrick R, Cullen BR (1988) Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes. Nature 335: 181–183.

38. Schnell T, Foley P, Wirth M, Münch J, Überla K (2000) Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum Gene Ther 11: 439–447.

39. Brandt S, Grunwald T, Lauts S, Stang A, Überla K (2006) Functional replacement of the R region of simian immunodeficiency virus-based vectors by heterologous elements. J Gen Virol 87: 2297–2307.

40. Michael NL, Herman SA, Kwok S, Dreyer K, Wang J, et al. (1999) Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J Clin Microbiol 37: 2557–2563.